ArticleRespiratory research2026
Artificial intelligence, machine learning-based automated fibrosis quantification in preclinical models of pulmonary fibrosis.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Next-Generation In Vitro Pulmonary Platforms for Respiratory Disease Modelling and Therapeutic Development: Current Advances and Future Prospects.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPrecise, quantitative assessment of disease features on histological images from preclinical models is essential for therapeutic development in diseases such as pulmonary fibrosis. However, current histological fibrosis scoring methods, such as Ashcroft Scoring have several limitations, including high time and labor requirements by expert pathologist readers, subjective semi-quantitative assessment and interobserver variability. The goal of this study was to assess the feasibility of a supervised AI/ML-based framework for automated, rapid, objective quantification of fibrosis content and spatial distribution in histology slides obtained from a variety of preclinical fibrosis models.
methodsLung histology slides stained with Masson’s trichrome were obtained from 194 individual mice from two independent cohorts of preclinical mouse models of pulmonary fibrosis. A supervised AI/ML algorithm was trained, validated and independently tested to automatically detect, segment and quantify fibrosis compared against independent Ashcroft scoring by an expert pathologist reader. Spatial distribution of AI/ML-segmented fibrosis patterns were compared across histology images.
resultsAI/ML-based fibrosis quantification demonstrated strong correlation with Ashcroft score, both in the validation cohort (Spearman ρ = 0.85, CI: 0.72–0.92), and in the independent, de novo test cohort (Spearman ρ = 0.89, CI: 0.84–0.93) with rapid assessment time (~ 1.5 times faster). Additionally, Ripley’s K analysis revealed differences in spatial distribution of AI-segmented fibrosis patterns among samples with similar Ashcroft scores and overall fibrosis content.
conclusionsThe AI/ML framework developed and independently validated in this study provides a robust, computationally-efficient method for precise, user-friendly, objective measurement of fibrosis content and spatial distribution, which would have major utility in preclinical therapeutic trials and investigations of disease pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.